Preview Mode Links will not work in preview mode

Oct 29, 2026

Featuring an interview with Dr Erica Mayer, including the following topics:

  • Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00)
  • Investigator Survey Results on Risk Assessment and Genomic Assays (20:07)
  • Adjuvant CDK4/6 Inhibitors for High-Risk,...


Oct 28, 2026

Featuring perspectives from Dr Lindsey Roeker, including the following topics:

  • Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00)
  • Case: A man in his late 70s with...


Oct 28, 2026

Featuring perspectives from Dr Lindsey Roeker, including the following topics:

  • Consensus Approach to optimizing front-line treatment (0:00)
  • Emerging role of sonrotoclax (8:39)
  • Bruton tyrosine kinase inhibitor monotherapy for older patients; discontinuation (14:48)
  • Evolving role of minimal residual disease...


Oct 27, 2026

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

  • Case: A woman in her early 70s with endometrioid carcinoma of the ovary and a large solitary brain metastasis after primary debulking surgery...


Oct 26, 2026

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

  • Case: A woman in her late 60s with a germline BRCA2 mutation and heavily pretreated ovarian cancer receives weekly nab paclitaxel and...